Monopar Therapeutics Inc (MNPR) 13F Holders & Ownership Data (98 Funds, Q2 2026)

MNPR ranks #4657 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

98 institutions disclose a position in MNPR, but none treat it as a major bet — even Saturn V Capital Management LP, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

GAMMA Investing LLC has added to its MNPR position for two straight quarters, increasing it by $1.5K to reach $3.1K today.

MNPR is down 2.4% today, but institutions show net buying of $34.4M this quarter — a divergence between today's price move and the underlying institutional flow.

MNPR reported a net loss of $17.8M over the trailing twelve months.

• Not yet profitable — net loss of $17.8M over the trailing twelve months
• Net income declined year over year, from -$17.3M to -$17.8M
• Operating cash flow was negative, using $12.2M in cash
• Current ratio of 51.35x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.02x equity — within a conventional range